Purchase this article with an account.
Z.-H. Song, Z. Qiao; Abnormal-Cannabidiol-Induced Increase in Aqueous Humor Outflow. Invest. Ophthalmol. Vis. Sci. 2010;51(13):145. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study the effects of abnormal-cannabidiol (aCBD), a non-CB1/CB2 cannabinoid agonist, on aqueous humor outflow via the trabecular meshwork pathway.
The effects of aCBD on aqueous humor outflow via the trabecular meshwork pathway were measured using a porcine anterior segment perfused organ culture model. Different concentrations of aCBD were administered to the perfusion medium and the aqueous humor outflow facility was monitored for 5 hours. To investigate whether non-CB1/CB2 cannabinoid receptors are involved in the aCBD-induced outflow effects, O-1918, a cannabidiol analog that acts as a selective antagonist at the non-CB1/CB2 receptors, was administered to the perfused anterior chamber 30 minutes prior to the application of aCBD. CB1 antagonist SR141716A or CB2 antagonist SR144528 was also used to investigate the possible involvement of CB1 or CB2 receptors, respectively, in the outflow effects induced by aCBD.
Administration of aCBD caused a concentration-dependent enhancement of aqueous humor outflow facility, with the maximum effect (155 ± 11.7 % of basal outflow facility) achieved at 5 hour after the administration of 30 nM of aCBD. Pretreatment with 1 µM of O-1918 produced a full antagonism on the aCBD-induced increase of aqueous humor outflow facility. Pretreatment with either 1 µM of SR141716A or 1 µM SR144528 had no effect on aCBD-induced enhancement of aqueous humor outflow facility.
The results from this study demonstrate that abnormal-cannabidiol increases aqueous humor outflow through the trabecular meshwork pathway, and these effects are mediated by non-CB1/CB2 cannabinoid receptors.
This PDF is available to Subscribers Only